Prognostic ability of DNA‑binding protein inhibitor ID‑1 expression in patients with oral squamous cell carcinoma

Chen,Jian; Zhang,Fan; Wang,Dong; Yang,Zhongjun; Liu,Shaohua; Dong,Zuoqing

doi:10.3892/ol.2020.11506

Prognostic ability of DNA‑binding protein inhibitor ID‑1 expression in patients with oral squamous cell carcinoma

Authors:
- Jian Chen
- Fan Zhang
- Dong Wang
- Zhongjun Yang
- Shaohua Liu
- Zuoqing Dong
View Affiliations

Affiliations: Department of Oral and Maxillofacial Surgery, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China, Department of Orthodontics, School and Hospital of Stomatology, Shandong University Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China, Department of Oral and Maxillofacial Surgery, Qilu Hospital of Shandong University, Qingdao, Shandong 266035, P.R. China
Published online on: April 2, 2020 https://doi.org/10.3892/ol.2020.11506
Pages: 3917-3922
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

DNA-binding protein inhibitor ID-1 (ID-1) plays a vital role in the development of cancer. In the present study, ID‑1 expression in oral squamous cell carcinoma (OSCC), and its association with prognosis were investigated in 128 patients with OSCC, treated at the Qilu Hospital of Shandong University and followed up for an additional 10 years. Immunohistochemical analysis was performed to detect ID‑1 expression, and the association between ID‑1 expression and recurrence, and estimated disease‑specific survival (DSS) time were subsequently analyzed using the Mann‑Whitney U test and the Kaplan‑Meier method, respectively. In addition, the log‑rank test was implemented to compare the survival curves and multivariate Cox proportional hazards analysis was performed to assess the prognostic value of ID‑1. The results demonstrated that ID‑1 was highly expressed in the majority of OSCC tissues investigated, and ID‑1 expression was significantly higher in cases with recurrence of local tumors and lymph node metastasis. Furthermore, higher ID‑1 expression levels were associated with a shorter DSS time. Taken together, the results of the present study suggest that ID‑1 may serve as an independent prognostic factor to predict DSS time in patients with OSCC.

View Figures

View References

1	Chow LQM: Head and neck cancer. N Engl J Med. 382:60–72. 2020. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
3	Shield KD, Ferlay J, Jemal A, Sankaranarayanan R, Chaturvedi AK, Bray F and Soerjomataram I: The global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2012. CA Cancer J Clin. 67:51–64. 2017. View Article : Google Scholar : PubMed/NCBI
4	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
5	Chinn SB and Myers JN: Oral cavity carcinoma: Current management, controversies, and future directions. J Clin Oncol. 33:3269–3276. 2015. View Article : Google Scholar : PubMed/NCBI
6	Schindl M, Schoppmann SF, Ströbel T, Heinzl H, Leisser C, Horvat R and Birner P: Level of Id-1 protein expression correlates with poor differentiation, enhanced malignant potential, and more aggressive clinical behavior of epithelial ovarian tumors. Clin Cancer Res. 9:779–785. 2003.PubMed/NCBI
7	Sun W, Guo MM, Han P, Lin JZ, Liang FY, Tan GM, Li HB, Zeng M and Huang XM: Id-1 and the p65 subunit of NF-κB promote migration of nasopharyngeal carcinoma cells and are correlated with poor prognosis. Carcinogenesis. 33:810–817. 2012. View Article : Google Scholar : PubMed/NCBI
8	Lin J, Guan Z, Wang C, Feng L, Zheng Y, Caicedo E, Bearth E, Peng JR, Gaffney P and Ondrey FG: Inhibitor of differentiation 1 contributes to head and neck squamous cell carcinoma survival via the NF-kappaB/survivin and phosphoinositide 3-kinase/Akt signaling pathways. Clin Cancer Res. 16:77–87. 2010. View Article : Google Scholar : PubMed/NCBI
9	Benezra R, Davis RL, Lockshon D, Turner DL and Weintraub H: The protein Id: A negative regulator of helix-loop-helix DNA binding proteins. Cell. 61:49–59. 1990. View Article : Google Scholar : PubMed/NCBI
10	Perk J, Iavarone A and Benezra R: Id family of helix-loop-helix proteins in cancer. Cancer. 5:603–614. 2005.PubMed/NCBI
11	Dong Z, Liu S, Zhou C, Sumida T, Hamakawa H, Chen Z, Liu P and Wei F: Overexpression of Id-1 is associated with tumor angiogenesis and poor clinical outcome in oral squamous cell carcinoma. Oral Oncol. 46:154–157. 2010. View Article : Google Scholar : PubMed/NCBI
12	Nishimine M, Nakamura M, Mishima K, Kishi M, Kirita T, Sugimura M and Konishi N: Id proteins are overexpressed in human oral squamous cell carcinomas. J Oral Pathol Med. 32:350–357. 2003. View Article : Google Scholar : PubMed/NCBI
13	Zhao J, Wang S, Liu N and Tang X: Correlation between the expression of Id-1 and hyperthermia-associated molecules in oral squamous cell carcinoma. J Clin Pathol. 66:758–763. 2013. View Article : Google Scholar : PubMed/NCBI
14	Lydiatt WM, Patel SG, O'Sullivan B, Brandwein MS, Ridge JA, Migliacci JC, Loomis AM and Shah JP: Head and neck cancers-major changes in the American joint committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 67:122–137. 2017. View Article : Google Scholar : PubMed/NCBI
15	Schoppmann SF, Schindl M, Bayer G, Aumayr K, Dienes J, Horvat R, Rudas M, Gnant M, Jakesz R and Birner P: Overexpression of Id-1 is associated with poor clinical outcome in node negative breast cancer. Int J Cancer. 104:677–682. 2003. View Article : Google Scholar : PubMed/NCBI
16	Kyrgidis A, Tzellos TG, Kechagias N, Patrikidou A, Xirou P, Kitikidou K, Bourlidou E, Vahtsevanos K and Antoniades K: Cutaneous squamous cell carcinoma (SCC) of the head and neck: Risk factors of overall and recurrence-free survival. Eur J Cancer. 46:1563–1572. 2010. View Article : Google Scholar : PubMed/NCBI
17	Wu JM and Montgomery E: Classification and pathology. Surg Clin North Am. 88:483–520. 2008. View Article : Google Scholar : PubMed/NCBI
18	Ke J, Wu R, Chen Y and Abba ML: Inhibitor of DNA binding proteins: Implications in human cancer progression and metastasis. Am J Transl Res. 10:3887–3910. 2018.PubMed/NCBI
19	Li L, Wei X, Wu B, Xiao Y, Yin M and Yang Q: siRNA-mediated knockdown of ID1 disrupts Nanog- and Oct-4-mediated cancer stem cell-likeness and resistance to chemotherapy in gastric cancer cells. Oncol Lett. 13:3014–3024. 2017. View Article : Google Scholar : PubMed/NCBI
20	Georgiadou D, Sergentanis TN, Sakellariou S, Filippakis GM, Zagouri F, Vlachodimitropoulos D, Psaltopoulou T, Lazaris AC, Patsouris E and Zografos GC: VEGF and Id-1 in pancreatic adenocarcinoma: Prognostic significance and impact on angiogenesis. Eur J Surg Oncol. 40:1331–1337. 2014. View Article : Google Scholar : PubMed/NCBI
21	Zhao ZR, Zhang ZY, Zhang H, Jiang L, Wang MW and Sun XF: Overexpression of Id-1 protein is a marker in colorectal cancer progression. Oncol Rep. 19:419–424. 2008.PubMed/NCBI
22	Li J, Li Y, Wang B, Ma Y and Chen P: Id-1 promotes migration and invasion of non-small cell lung cancer cells through activating NF-κB signaling pathway. J Biomed Sci. 24:952017. View Article : Google Scholar : PubMed/NCBI
23	Hu Y, Luo KJ, Wen J and Zhu ZH: Strong expression of Id-1 in metastatic lymph nodes from esophageal squamous cell carcinoma is associated with better clinical outcome. J Thorac Dis. 10:5499–5507. 2018. View Article : Google Scholar : PubMed/NCBI
24	Yuen HF, Chan YP, Chan KK, Chu YY, Wong ML, Law SY, Srivastava G, Wong YC, Wang X and Chan KW: Id-1 and Id-2 are markers for metastasis and prognosis in oesophageal squamous cell carcinoma. Br J Cancer. 97:1409–1415. 2007. View Article : Google Scholar : PubMed/NCBI
25	Fidler IJ and Hart IR: Biological diversity in metastatic neoplasms: Origins and implications. Science. 217:998–1003. 1982. View Article : Google Scholar : PubMed/NCBI
26	Zhang X, Yin X, Zhang H, Sun G, Yang Y, Chen J, Zhu X, Zhao P, Zhao J, Liu J, et al: Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma. BMC Cancer. 19:3602019. View Article : Google Scholar : PubMed/NCBI
27	Hao X, Sun B, Hu L, Lähdesmäki H, Dunmire V, Feng Y, Zhang SW, Wang H, Wu C, Wang H, et al: Differential gene and protein expression in primary breast malignancies and their lymph node metastases as revealed by combined cDNA microarray and tissue microarray analysis. Cancer. 100:1110–1122. 2004. View Article : Google Scholar : PubMed/NCBI
28	Inari H, Suganuma N, Kawachi K, Yoshida T, Yamanaka T, Nakamura Y, Yoshihara M, Nakayama H, Yamanaka A, Masudo K, et al: Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: Exploratory study using primary and paired metastatic lesions. BMC Cancer. 17:1602017. View Article : Google Scholar : PubMed/NCBI
29	Patel SG, Amit M, Yen TC, Liao CT, Chaturvedi P, Agarwal JP, Kowalski LP, Ebrahimi A, Clark JR, Cernea CR, et al: Lymph node density in oral cavity cancer: Results of the international consortium for outcomes research. Br J Cancer. 109:2087–2095. 2013. View Article : Google Scholar : PubMed/NCBI
30	Tabatabaeifar S, Larsen MJ, Larsen SR, Kruse TA, Thomassen M and Sørensen JA: Investigating a case of possible field cancerization in oral squamous cell carcinoma by the use of next-generation sequencing. Oral Oncol. 68:74–80. 2017. View Article : Google Scholar : PubMed/NCBI
31	Soroceanu L, Murase R, Limbad C, Singer E, Allison J, Adrados I, Kawamura R, Pakdel A, Fukuyo Y, Nguyen D, et al: Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target. Cancer Res. 73:1559–1569. 2013. View Article : Google Scholar : PubMed/NCBI
32	Dong Z, Wei F, Zhou C, Sumida T, Hamakawa H, Hu Y and Liu S: Silencing Id-1 inhibits lymphangiogenesis through down-regulation of VEGF-C in oral squamous cell carcinoma. Oral Oncol. 47:27–32. 2011. View Article : Google Scholar : PubMed/NCBI
33	Xiao F, Qiu H, Cui H, Ni X, Li J, Liao W, Lu L and Ding K: MicroRNA-885-3p inhibits the growth of HT-29 colon cancer cell xenografts by disrupting angiogenesis via targeting BMPR1A and blocking BMP/Smad/Id1 signaling. Oncogene. 34:1968–1978. 2015. View Article : Google Scholar : PubMed/NCBI